Subsequent studies have shown that MDM2 is overexpressed and amplified in several hematological cancers and solid tumors, and high MDM2 levels are associated with a poor prognosis in patients with cancer [2,3,4]. Here, MDM2 is linked to hematopoietic and lymphoid cell neoplasm.